AlphaQuest LLC Has $421,000 Holdings in Tyra Biosciences, Inc. $TYRA

AlphaQuest LLC reduced its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 58.9% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 30,060 shares of the company’s stock after selling 43,013 shares during the period. AlphaQuest LLC owned about 0.06% of Tyra Biosciences worth $421,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Federated Hermes Inc. boosted its position in shares of Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after buying an additional 1,841 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after acquiring an additional 1,668 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Tyra Biosciences in the third quarter valued at about $133,000. Intech Investment Management LLC boosted its holdings in Tyra Biosciences by 46.5% during the second quarter. Intech Investment Management LLC now owns 19,919 shares of the company’s stock worth $191,000 after purchasing an additional 6,322 shares during the last quarter. Finally, Corton Capital Inc. bought a new stake in Tyra Biosciences in the 2nd quarter worth about $233,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on TYRA shares. Wedbush boosted their target price on Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Jefferies Financial Group raised their target price on Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday. Piper Sandler lifted their target price on Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, January 23rd. Wall Street Zen downgraded shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.17.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $31.00 on Friday. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $32.44. The business has a 50-day moving average of $26.81 and a 200 day moving average of $18.20. The firm has a market cap of $1.65 billion, a P/E ratio of -16.58 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). As a group, research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Robert J. More sold 246,871 shares of the business’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the sale, the director owned 3,833,425 shares of the company’s stock, valued at $77,626,856.25. The trade was a 6.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 15.20% of the company’s stock.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.